The supply chains of multinational pharmaceutical companies are undergoing a profound reorganization. Chinese CDMO (Contract Development and Manufacturing Organization) enterprises, with their strong technical strength, cost-effectiveness and continuously improving quality systems, have indeed won more and more international recognition and become highly favored partners among them.

Internationalization strategy and global layout

To better serve global customers and address uncertainties, some leading Chinese CDMO enterprises have adopted proactive internationalization strategies, including setting up R&D and production bases in key markets such as Europe and the United States through acquisitions or self-construction. This model that combines "in China, for the world" with "overseas, close to the future" offers customers greater flexibility and supply chain resilience.